← Oncology Approval Tracker

FDA DECISION ·

Tasigna

nilotinib · Novartis

FDA approvalNew or expanded indicationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Extends the accelerated-phase Philadelphia chromosome-positive chronic myeloid leukemia indication to children age 1 and older with resistance or intolerance to prior treatment.

LAMPGEN ANALYSIS

Why it matters

The decision covers a pediatric advanced-phase population beyond the existing chronic-phase pediatric use.

What research teams should watch

Verify disease phase, prior tyrosine kinase inhibitor response and pediatric dose calculation.

PRIMARY RECORDS

Sources